biogen inc previous biogen idec inc engag develop manufactur commerci therapi
compani product address diseas multipl sclerosi non-hodgkin lymphoma nhl rheumatoid arthriti ra crohn
diseas cd psoriasi compani four product avonex interferon rituxan rituximab tysabri
natalizumab fumaderm dimethylfumar monoethylfumar salt avonex use treatment relaps form
multipl sclerosi ms rituxan one sell oncolog therapeut unit state rituxan approv nhl
tysabri approv treatment relaps form ms fumaderm act immunomudul compani also
product candid oral fumar monoclon antibodi mab galiximab mab
lumiliximab human mab ocrelizumab lixivaptan oral compound potenti treatment hyponatremia
rank
return equiti
price book
incom statement summari figur billion
long-term fundament rank
biogen idec rank number list
medical/biomed compani trade today unit
state market capit billion
medical/biomed compani highest total
asset highest revenu
within sector rel low price-to-earnings low p/
strong rel roe roa
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit billion aggreg sector net profit
billion previou year
ebit billion aggreg sector ebit
billion previou year
mcap billion aggreg sector mcap
billion previou year
biogen idec inc place bss rank perform past year percentil rank
biogen idec inc new entrant pwc list top global compani rank mcap march
largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
carbon product wast product product
largest revenu forb global
new entrant industri week list world largest manufactur revenu rank
earn yield time bond yield
rise fall last three month number rise
outnumb fall
market stock unit trade
today stock rel strength
mean outperform market
indic exponenti move averag ema
minu ema posit
suggest bullish signal ema well
ema rise anoth bullish signal
price map ratio bullish indic
past day ratio exceed time
suggest upsid stock trade
map map
map bullish indic map
increas increas anoth bullish
return equiti versu sector averag
market averag
total liabilities/ebitda less compar
favour joseph piotroski benchmark
return asset versu sector averag
market averag
return capit employ versu sector averag
market averag
net profit margin averag last year
consid superior suggest high margin safeti
per du pont analysi return equiti high
comput net profit margin time
asset turnov sales/asset time leverag factor
total assets/sharehold equiti
also follow criteria set benjamin graham
current ratio two current asset time
stabil growth earn last year defin
two declin greater year-end
earn declin earn last
trail twelv month price-to-earnings cyclic
adjust price earn cape well cape
histor averag last year
cape develop economist robert shiller base
methodolog benjamin graham david dodd
smooth earn across period base move
averag quarter
growth quarterli revenu net incom
pcp quarterli revenu million
million
pcp quarterli net profit turnaround million
million
debt equiti ratio well within safe benchmark
figur moreov improv past three year
turnov quarter
return equiti
return asset
trail month idec gain past year
idec inc gain
past year close today compar
risen period
rel price increas valu
invest year ago vs
capit gain
stock score mere set
posit net incom posit oper cash-flow good qualiti
earn oper cash-flow exce net incom reduct
total share issu
price-to-earnings versu market averag
estim share trade current year price-to-earnings
forward year price-to-earnings
price/sal versu market averag
estim share trade current year price/sal
forward year price/sal
 ratio defin jame tobin mcap divid
total asset compar rest market
stock overvalu rank bottom quartil stock
valu ratio
averag annual compound return share price
last year under-perform averag
annual compound return
earn yield less benchmark yield
price sale
price book valu
price equal volum weight averag
price
biogen idec strengthen past quarter
biogen idec inc strengthen
past quarter close today
compar rose point
past quarter repres rel price
chang valu invest month ago
vs
capit gain
stock trade low
high averag daili volatil place
stock quartil market mean least
past year averag daili volum jump million share million share turnov period decreas year
month month
price increas fuell averag volum
price decreas fuell averag volum
price increas averag volum
price decreas averag volum
result report annual
us million except per share data share outstand
revenu therapeut program
expens
sale exclud amort impair acquir
research develop
sell gener administr
amort impair acquir intang asset
acquir in-process research develop
loss fair valu remeasur conting
total cost expens
incom oper
incom incom tax expens equiti loss
investe net tax
equiti loss investe net tax
net incom loss attribut non-controlling interest net tax
net incom attribut biogen inc
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
weighted-averag share use calcul
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
cash equival
due therapeut program
properti plant equip net
invest asset
current portion note payabl
accru expens
commit conting
accumul comprehens loss
treasuri stock cost million million share
total liabil equiti
flow oper activ
adjust reconcil net incom net cash flow
depreci amort impair
acquir in-process research develop
chang oper asset liabil net
due therapeut program
accru expens current liabil
incom tax asset liabil
net cash flow provid oper activ
flow invest activ
proce sale matur market secur
purchas market secur
conting consider relat fumapharm ag acquisit
acquir in-process research develop
purchas properti plant equip
acquisit intang asset
purchas inc stock
invest samsung bioepi
net cash flow use invest activ
flow financ activ
purchas treasuri stock
payment relat issuanc stock share-bas
net distribut non-controlling interest
repay borrow
net cash contribut bioverativ inc
net cash flow use financ activ
net increas decreas cash cash equival
effect exchang rate chang cash cash equival
cash equival begin year
cash equival end year
earn cont op margin
annual report biogen idec net profit
biogen idec report net profit year-end decemb
major chang compar previou year
total revenu
ebit total asset
total non-curr asset total asset
fix asset total asset
net tangibl asset per share
ebit margin
work capit total asset
retain earn total asset
total current asset total asset
total revenu total asset steadi
debt equiti steadi
total liabil total asset steadi
current ratio steadi
intang total asset
short-term invest total asset
profit/ loss tax
fig year-on-year comparison per share figur
fig year-on-year comparison perform ratio
return equiti
return asset
total debt net tangibl asset
total liabil ebitda
debt/equ
total liabilities/tot asset
current ratio
common size ratio asset
total non-curr asset total asset
intang total asset
total current asset total asset
fix asset total asset
short-term invest total asset
common size ratio sale
profit tax sale
sale market expens sale
good sold sale
tax expens sale
fig five-year record growth perform
last year total revenu averag ebitda averag net profit averag compound
annual growth rate compound-annual-growth-rate averag total revenu net profit ebitda
result report
us million except per share data share outstand
sale exclud amort acquir intang asset
revenu therapeut program
expens
research develop
sell gener administr
amort acquir intang asset
acquir in-process research develop
loss fair valu remeasur conting
total cost expens
incom oper
incom incom tax expens equiti loss
investe net tax
equiti loss investe net tax
netincom loss attribut non-controlling interest netoftax
net incom attribut biogen inc
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
weighted-averag share use calcul
basic earn per share attribut biogen inc
dilut earn per share attribut biogen inc
cash equival
due therapeut program
properti plant equip net
invest asset
current portion note payabl
accru expens
commit conting
accumul comprehens loss
treasuri stock cost
total liabil equiti
flow oper activ
adjust reconcil net incom net cash flow
depreci amort
acquir in-process research develop
chang oper asset liabil net
accru expens current liabil
incom tax asset liabil
chang oper asset liabil net
net cash flow provid oper activ
flow invest activ
proce sale matur market secur
purchas market secur
conting consider paid relat fumapharm ag
purchas properti plant equip
acquir in-process research develop
acquisit intang asset
purchas inc stock
net cash flow use invest activ
flow financ activ
purchas treasuri stock
payment relat issuanc stock share-bas
repay borrow
net distribut non-controlling interest
net cash contribut bioverativ inc
net cash flow use financ activ
net increas decreas cash cash equival
effect exchang rate chang cash cash equival
cash equival begin period
cash equival end period
profit tax
oper cash flow
sale
past year incom tax profit tax decreas
base issu equiti share market
capitalis billion largest
medical/biomed compani asset
today report full year fourth quarter financi
execut well strateg prioriti
execut offic made signific progress develop
expand pipelin well advanc multipl modal
potenti deliv new therapi patient
detail click
novemb biogen idec appoint robin kramer
biogen idec appoint robin kramer vice presid
appoint take effect
report buy sell trail month continu
share
share
report institut buy sell share
hold end quarter
report hold institut decemb
total report hold institut share
report hold institut
issu capit
net buying/ sell institut trail month ttm
usd valu
montreal
new york mellon corp
state new jersey common
state tennesse treasuri
board manag creation sharehold valu
board director year sinc appoint
mr vounatso serv chief execut offic
one director sinc januari prior
april appoint chief execut offic
serv execut vice presid chief commerci
offic prior join mr vounatso spent year
merck co inc pharmaceut compani
recent serv presid primari custom busi
merck custom centric role led merck
global primari care busi unit role encompass
biosimilar group develop institut strateg
framework enhanc compani relationship key
constitu includ signific provid payer
retail world largest govern mr vounatso
previous held leadership posit across europ china
merck prior mr vounatso held manag
posit ciba-geigi mr vounatso receiv
certif medicin universit victor segalen
bordeaux ii franc hec school
manag pari
mr vounatso signific knowledg experi
respect biotechnolog healthcar pharmaceut
servic execut pharmaceut industri
studi medicin part educ background
former public compani directorship held past
dr papadopoulo serv one director sinc
independ chairman sinc june dr
papadopoulo also serv chairman inc
drug discoveri develop compani co-found
inc biopharmaceut
compani previous invest banker cowen
 co llc financi servic compani focus
biotechnolog pharmaceut sector
retir vice chairman august prior join
cowen co dr papadopoulo serv year
invest banker painewebb inc financi servic
compani recent chairman
focus biotechnolog dr papadopoulo also director
bg medicin inc diagnost compani focus
develop commerci cardiovascular diagnost
work invest banker focus life
scienc industri dr papadopoulo bring board
director firsthand understand demand
establish grow run life scienc busi
scienc technolog
mr pangia serv director compani
period compani oper idec
pharmaceut serv director sinc
follow idec merger inc mr pangia
partner ivi capit partner llc gener partner ivi
healthcar capit privat equiti fund special
healthcar invest sinc
also chief execut offic ivi sport medicin llc
medic devic compani octob octob
also serv chief execut offic highland
mr pangia self-employ invest
banker held variou senior manag
posit painewebb financi servic compani
includ execut vice presid director invest
bank painewebb incorpor new york member
board director painewebb inc chairman
painewebb properti inc member sever
painewebb execut oper committe
mr pangia signific financi acumen breadth
expertis within healthcar industri
compens manag develop chair
former public compani directorship held past
former public compani directorship held past
jeffrey capello execut vice presid chief
offic mr capello join us decemb
execut vice presid chief offic bring
year experi financ recent execut
vice presid chief offic beacon health
option inc previou experi includ found
run compani monomi advisor serv
chief offic ortho clinic diagnost boston
scientif corpor earlier career
partner boston amsterdam offic pwc
believ mr capello strong public compani financi
experi allow play critic role aim
execut busi strategi pursu busi develop
opportun build pipelin
dr sherwin serv one director sinc
dr sherwin current divid time advisori work
life scienc industri patient care teach
specialti medic oncolog clinic professor
medicin univers california san francisco
volunt attend physician hematology-oncolog
current serv ventur partner third ventur
llc dr sherwin previous serv chairman
ceregen inc life scienc compani co-found
acquisit sangamo bioscienc inc
also co-found chairman abgenix inc
antibodi compani acquir amgen inc
octob serv chief
execut offic cell genesi inc life scienc compani
chairman compani merger
inc inc
octob prior held variou posit
genentech inc life scienc compani recent vice
presid clinic research dr sherwin member
board director inc neurocrin
bioscienc inc clinical-stag life scienc
dr sherwin extens knowledg life scienc
industri bring year experi senior
leadership posit larg small publicli trade life
scienc compani board director
ms dorsa serv one director sinc
ms dorsa serv execut vice presid chief
financi offic public servic enterpris group
incorpor diversifi energi compani april
retir octob serv board
director februari april februari
april serv senior vice presid global
human health strategi integr merck co inc
pharmaceut compani novemb januari
ms dorsa serv senior vice presid chief
financi offic inc life scienc
compani februari novemb serv
senior vice presid chief offic avaya
inc telecommun compani januari
ms dorsa held variou financi oper posit
merck co inc includ vice presid treasur
execut director custom market execut
director price strateg plan ms dorsa also
serv director inc
inc biotechnolog compani
truste goldman sach etf trust goldman sach
energi renaiss fund goldman sach
incom opportun fund invest fund within
ms dorsa signific financi account expertis
deep knowledg pharmaceut industri strateg
perspect industri particularli valuabl board
director overse growth initi review
intern develop project extern opportun
scienc technolog
former public compani directorship held past
former public compani directorship held past
mr posner serv one director sinc
mr posner privat investor sinc march
presid point rider group llc consult
advisori servic firm serv predominantli financi
servic industri well institut investor seek
make control invest industri march
mr posner serv presid chief execut
offic co-chief invest offic clearbridg advisor
llc asset manag compani wholly-own
subsidiari prior mr posner co-found
hygrov partner llc privat invest fund
serv manag five year serv
portfolio manag analyst fidel invest
financi servic compani
warburg pincu asset management/credit suiss
asset manag also serv co-chief
invest offic director research mr posner also
serv director aqr fund ltd
specialti insur reinsur provid
given substanti experi lead institut
invest manag advisor mr posner bring
profession investor perspect signific manag
financi expertis valuabl board director
overse strategi enhanc stockhold valu
former public compani directorship held past
ms schenk serv director compani
period compani oper idec
pharmaceut serv director sinc
follow idec merger inc ms schenk
attorney consult privat practic extens public
polici busi experi also member
board overs scripp research institut director
california high speed rail author board truste
univers california san diego foundat
serv chief staff governor
california time led effort creat
institut scienc innov univers
california head state execut branch risk
manag team post california energi
crisi ms schenk member
unit state hous repres repres san
diego california serv hous energi commerc
committe special emphasi biotechnolog
california secretari busi
transport hous time form
california commiss industri innov ms schenk
member board director energi
servic develop compani serv
compens committe execut committe
chair environment health safeti technolog
committe ms schenk also nation associ
member nacd advisori council risk oversight
fellow ucla luskin school public affair ms
schenk select nacd directorship honore
ms schenk strong public polici govern legal privat
sector experi provid vital insight board director
signific issu affect highli regul life
scienc industri bring public sector oper
manag expertis board director
demonstr commit boardroom excel
complet nacd comprehens program studi
corpor director supplement skill set
on-going engag director commun access
compens manag develop
former public compani directorship held past
experi dr denner serv one director
sinc dr denner found partner chief
invest offic sarissa capit manag lp
regist invest advisor found
sarissa capit focus improv strategi
compani enhanc stockhold valu
dr denner serv senior manag director icahn
capit prior serv portfolio manag vike
global investor privat invest fund
denner also director medicin compani
qualif dr denner signific experi overse
oper research develop healthcar
compani evalu corpor govern matter
also extens experi investor particularli
respect healthcar compani possess broad
former public compani directorship held past
dr rowinski serv one director sinc
serv presid rgenix inc privately-held life
scienc compani sinc novemb execut
also chief scientif offic clearpath
develop co rapidli advanc develop stage
therapeut asset pre-defin human proof-of-concept
mileston januari novemb dr
rowinski head research develop
chief medic offic inc
biotechnolog compani focus discoveri
develop therapeut target cancer stem cell dr
rowinski adjunct professor medicin new york
univers independ consult sinc
januari prior chief medic offic
focus develop therapeut polycyst kidney
diseas august acquisit septemb
decemb serv chief
medic offic execut vice presid imclon
system incorpor life scienc compani
dr rowinski held sever posit cancer therapi
 research center institut drug develop includ
director institut director clinic research
time held sbc endow chair earli drug
develop clinic professor medicin univers
texa scienc center san antonio
dr rowinski associ professor oncolog
john hopkin school medicin staff
john hopkin hospit dr rowinski serv director
fortress biotech inc biopharmaceut compani
dr rowinski extens research drug develop
experi broad scientif medic knowledg
biogen committe membership compens
scienc technolog
former public compani directorship held past
ms leam serv one director sinc
ms leam independ consult sinc
serv chief execut offic
presid tuft health provid healthcar
insur ms leam serv sever
execut posit tuft health includ presid
chief oper offic chief offic
ms leam well-develop leadership skill financi
acumen provid insight healthcar reimburs
payer market serv year senior
oper financi manageri role
former public compani directorship held past
dr mulligan serv one director sinc
dr mulligan current professor genet
emeritu harvard medic school serv
professor genet director harvard
gene therapi initi also current
serv portfolio manag icahn capit lp posit
held sinc march prior harvard dr mulligan
professor molecular biolog massachusett institut
technolog member whitehead institut biomed
research chief scientif offic somatix therapi
corpor drug discoveri develop compani
found dr mulligan found partner sarissa capit
manag lp regist invest advisor
dr mulligan name macarthur foundat fellow
dr mulligan scientif expertis area molecular
biolog genet gene therapi biotechnolog well
extens experi within healthcar industri includ
overse oper research develop
scienc technolog chair
compens manag develop
former public compani directorship held past
susan alexand execut vice presid chief legal
corpor servic secretari serv
execut committe sinc prior
decemb ms alexand serv execut vice
presid gener counsel corpor secretari
januari ms alexand serv senior vice
presid gener counsel corpor secretari
servic compani ms alexand serv
gener counsel softwar compani
ms alexand serv counsel
corpor specialti chemic perform materi
compani prior ms alexand partner law
firm hinckley allen snyder fine ambrogn ms
alexand receiv wellesley colleg
boston univers school law
mr guindo bring year experi global
pharmaceut industri held sever leadership
posit merck known msd outsid canada
usa canada usa franc africa netherland
work sever disciplin includ financ sale
market gener manag global strategi product
develop specialti acut hospit care recent
mr guindo presid manag director merck
price period/numb period
price close today/pric close period ago rank
percentil within entir market
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock exchang toronto stock exchang
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
